420 results on '"Lengfelder, Eva"'
Search Results
102. Rituximab Overcomes Sex as a Strong Adverse Prognostic Factor for Treatment Outcome in Patients with Follicular Lymphoma: Analysis of Patients Treated with Rituximab/CHOP or CHOP in Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG).
103. Rituximab Maintenenance Therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma – Final Results of a Multicenter Prospective Randomised Phase II Study.
104. Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
105. Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group
106. Pregnancies in Patients with Philadelphia Negative Chronic Myeloproliferative Disorders: Interim Report of the European LeukemiaNet Data Base
107. Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months
108. Autologous Stem Cell Transplantation after Myeloablative Therapy in First Remission May Be Beneficial in Patients with Advanced Stage Follicular Lymphoma after Front-Line Therapy with R-CHOP. An Analysis of Two Consecutive Studies of the German Low Grade Lymphoma Study Group (GLSG)
109. Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers
110. Older Age Is An Independent Risk Factor in AML
111. CNS-Disease in Elderly Patients Treated with Modern Chemotherapy (CHOP-14) with or without Rituximab: An Analysis of CNS Events in the RICOVER-60 Trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL).
112. Response Adapted Assignment of the Number of Chemotherapy Cycles for the Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Is Not Justified: Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
113. Subcutaneous Alemtuzumab (MabCampath) in Fludarabine-Refractory CLL (CLL2H Trial of the GCLLSG).
114. In Reply
115. Rituximab Is the Essential Treatment Modality That Underlies the Significant Improvement in Short and Long Term Outcome of Patients with Advanced Stage Follicular Lymphoma - A 10 Year Analysis of GLSG Trials.
116. Front - Line Combined Immuno-Chemotherapy (R-CHOP) Significantly Improves the Time to Treatment Failure and Overall Survival in Elderly Patients with Advanced Stage Follicular Lymphoma - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).
117. Six vs. Eight Cycles of Bi-Weekly CHOP-14 with or without Rituximab for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Completed RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
118. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2‐PDGFRA fusion gene
119. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha
120. A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples
121. Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
122. Transient Response to Imatinib in an Atypical Chronic Myeloproliferative Disease Associated with ins(9;4)(q34;q21q31) and a CDK5RAP2-PDGFRA Fusion Gene.
123. Treatment of older patients with AML
124. Treatment concepts of acute promyelocytic leukemia
125. The Addition of Rituximab to Combination Chemotherapy with CHOP Has a Long Lasting Impact on Subsequent Treatment in Remission in Follicular Lymhoma but Not in Mantle Cell Lymphoma: Results of Two Prospective Randomized Studies of the German Low Grade Lymphoma Study Group (GLSG).
126. CHOP Improves Response Rates but Not Overall Survival in Follicular and Mantle Cell Lymphoma (MCL)- Results of a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).
127. Treatment with Pegylated Interferon α (PegIntron) for High-Risk Essential Thrombocythemia: Results of a Phase II Study.
128. Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia
129. Rapid diagnostic approach to PML-RARα-positive acute promyelocytic leukemia
130. Should a platelet limit of 600 × 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages
131. Osteoporosis in severe congenital neutropenia: Inherent to the disease or a sequela of G-CSF treatment?
132. Interferon-alpha in the Treatment of Essential Thrombocythemia
133. Interleukin-2 Bolus Infusion as Late Consolidation Therapy in 2nd Remission of Acute Myeloblastic Leukemia
134. Atypical mRNA fusions in PML-RARA positive, RARA-PML negative acute promyelocytic leukemia.
135. Pathogenesis, Diagnosis and Monitoring of Residual Disease in Acute Promyelocytic Leukaemia.
136. Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia.
137. Should a platelet limit of 600 × 10[sup 9]/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages.
138. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomasThe authors dedicate this paper to Reza Parwaresch, who served as a reference pathologist for the German Low‐Grade Lymphoma Study Group (GLSG) over many years and who died unexpectedly in November 2005.: Results of a prospective randomized trial of the German Low‐Grade Lymphoma Study Group
139. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
140. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
141. Widespread occurrence of the JAK2V617F mutation in chronic myeloproliferative disorders
142. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process.
143. Double Induction Strategy for Acute Myeloid Leukemia: The Effect of High-Dose Cytarabine With Mitoxantrone Instead of Standard-Dose Cytarabine With Daunorubicin and 6-Thioguanine: A Randomized Trial by the German AML Cooperative Group
144. Subcutaneous Campath-1H (Alemtuzumab) in Fludarabine-Refractory Cll: Interim Analysis of the CLL2h Study of the German Cll Study Group (GCLLSG).
145. Validation of a Molecular Risk Score for Prognosis of Patients With Acute Promyelocytic Leukemia Treated With All-trans Retinoic Acid and Chemotherapy-containing Regimens.
146. Different Impact of Expression Levels of IGFBP2and IGFBP7on Survival and Relapse Rate in Acute Promyelocytic Leukemia
147. Next Generation RNA Sequencing of Acute Promyelocytic Leukemia (APL) Identifies Novel Long Non Coding RNAs Including New Variants of MIR181A1HGThat Are Differentially Expressed during Myeloid Differentiation
148. Transient Response to Imatinib in an Atypical Chronic Myeloproliferative Disease Associated with ins(9;4)(q34;q21q31) and a CDK5RAP2-PDGFRAFusion Gene.
149. RNA-sequencing of acute promyelocytic leukemia primary blasts reveals novel molecular biomarkers of early death events.
150. Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.